Linezolid Patent Expiration
Linezolid is used for treating microbial infections. It was first introduced by Pfizer Inc
Linezolid Patents
Given below is the list of patents protecting Linezolid, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zyvox |
US6514529 (Pediatric) | Oxazolidinone tablet formulation |
Sep 15, 2021
(Expired) | Pfizer |
| Zyvox |
US6559305 (Pediatric) | Linezolid—crystal form II |
Jul 29, 2021
(Expired) | Pfizer |
| Zyvox | US6514529 | Oxazolidinone tablet formulation |
Mar 15, 2021
(Expired) | Pfizer |
| Zyvox | US6559305 | Linezolid—crystal form II |
Jan 29, 2021
(Expired) | Pfizer |
| Zyvox | US6559305 | Linezolid—crystal form II |
Jan 29, 2021
(Expired) | Pfizer |
| Zyvox |
US5688792 (Pediatric) | Substituted oxazine and thiazine oxazolidinone antimicrobials |
May 18, 2015
(Expired) | Pfizer |
| Zyvox | US5688792 | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Nov 18, 2014
(Expired) | Pfizer |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Linezolid's patents.
Latest Legal Activities on Linezolid's Patents
Given below is the list recent legal activities going on the following patents of Linezolid.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Correspondence Address Change Critical
| 29 Aug, 2014 | US6559305(Litigated) |
| Correspondence Address Change Critical
| 28 Aug, 2014 | US6514529 |
| Patent Issue Date Used in PTA Calculation Critical
| 06 May, 2003 | US6559305(Litigated) |
| Recordation of Patent Grant Mailed Critical
| 06 May, 2003 | US6559305(Litigated) |
| Issue Notification Mailed Critical
| 17 Apr, 2003 | US6559305(Litigated) |
| Receipt into Pubs | 07 Apr, 2003 | US6559305(Litigated) |
| Application Is Considered Ready for Issue Critical
| 03 Apr, 2003 | US6559305(Litigated) |
| Receipt into Pubs | 02 Apr, 2003 | US6559305(Litigated) |
| Receipt into Pubs | 03 Mar, 2003 | US6559305(Litigated) |
| Workflow - File Sent to Contractor | 03 Mar, 2003 | US6559305(Litigated) |
Linezolid's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Linezolid:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
